• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·STSN
Share

Stemsation International, Inc. Stocks

$ 0.02Last Updated 30.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 1.67M

$ 0.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

StemSation International, Inc., headquartered in Boca Raton, Florida, specializes in the development, manufacture, and distribution of natural wellness products. These offerings are specifically designed to bolster the human body's stem cell and endocannabinoid systems. Among its key products is StemRCM, a nutritional supplement created to enhance stem cells' natural capacity to mend, rejuvenate, and revitalize bodily tissues and organs. This is achieved by promoting healthy stem cell liberation, transport, and targeting within the system. The company markets its goods directly to consumers through a network of independent health advocates.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'expensive' on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

01.08.2026 01:30

Alibaba Supplied 20,000 Nvidia Chips to the Creator of Kimi K3 — Bloomberg

01.08.2026 00:22

"These scars have cost us dearly": "AI Nostradamus" promised not to borrow money anymore

31.07.2026 22:26

The Kazakh Market: CPC as a Risk Factor, the Summer Slowdown, and Weakening Support for the Tenge

31.07.2026 21:55

Roblox shares plummeted 30%. Analysts have begun advising investors to sell them

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026